Mymetics Corporation

Equities

MYMX

US62856A3005

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 12:47:38 2024-02-16 EST			5-day change	1st Jan Change
0.01 ^USD	-96.16%		-.--%	-99.69%

2023	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020

May 15, 2020 at 07:59 am

Mymetics Corporation announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced total revenue was EUR 272,000. Operating loss was EUR 481,000 compared to EUR 559,000 a year ago. Net loss was EUR 1.164 million compared to EUR 1.228 million a year ago.

Latest news about Mymetics Corporation

Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-11	CI
Mymetics Corporation Auditor Raises 'Going Concern' Doubt	23-04-10	CI
Mymetics Corporation Appoints Marcel B. Rüegg to the Board	23-01-17	CI
Mymetics Corporation Announces Resignation of Ernest M. Stern as A Member of the Board of Directors	22-12-28	CI
Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Mymetics Corporation Auditor Raises 'Going Concern' Doubt	22-03-30	CI
Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Mymetics Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-18	CI
Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-31	CI
Mymetics Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-13	CI
Mymetics Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-13	CI
Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-15	CI
Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-30	CI
Mymetics Corporation Auditor Raises 'Going Concern' Doubt	20-03-29	CI
Mymetics Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Mymetics Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-13	CI
Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-15	CI
Mymetics and Texas Biomedical Research Institute Receive HIV Vaccine Funding from the National Institutes of Health	19-04-29	CI

Chart Mymetics Corporation

Duration

Period

More charts

Company Profile

Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MYMETICS CORPORATION	-99.69%	1.52K
VERTEX PHARMACEUTICALS INCORPORATED	+7.75%	113B
REGENERON PHARMACEUTICALS, INC.	+10.36%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.93%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.53%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.01%	14.29B
SAREPTA THERAPEUTICS, INC.	+36.20%	12.52B

Bio Therapeutic Drugs